Nxera Pharma Co., Ltd. · TSE:4565

Nxera Pharma — Sosei Group — 36th Annual J.P. Morgan Healthcare Conference (January 2018)

20 slides from Nxera Pharma's conference presentation, Jan 8, 2018

  1. Slide 1: Introduction to Sosei Group

    Sosei Group Corporation 36 th Annual J.P. Morgan INTRODUCTION TO Healthcare SOSEI GROUP Conference 8 January 2018 July 2017

  2. Slide 2: Disclaimer

    Disclaimer The material that follows is a presentation of general background information about Sosei Group Corporation and its subsidiaries (collectively, the “Company”) as of the date of this presentation. This material has been prepared solely for informational purposes and is not to be construed

  3. Slide 3: A Japan-listed biotech with a difference

    Listed 2004 in Tokyo (TSE Mothers: 4565) Global management team A Japan-listed biotech with a difference Main scientific campus in the U.K. Market capitalization: c.$2.0bn ➢ World-leader in GPCR-focused drug design based on unique IP protected StaR®1 GPCR technology & enabled SBDD2 platform ➢ Partne

  4. Slide 4: Unique management team for a Japan-listed company

    Unique management team for a Japan-listed company Significant pharma and biotech expertise Peter BAINS Dr. Malcolm WEIR Dr. Fiona MARSHALL Chief Executive Officer Chief R&D Officer Chief Scientific Officer  Former Senior VP of International Commercial  CEO and Co-Founder Heptares  CSO and Co-Foun

  5. Slide 5: Three corporate events have shaped Sosei

    Three corporate events have shaped Sosei Our world-leading Partners 2005 2015 2017 Acquired Acquired Investment in Arakis Heptares Tx MiNA Tx (UK) (UK) (UK) ➢ Glycopyrrolate, later ➢ Platform: StaR® ➢ Platform: small licensed to NVS for technology for activating RNA respiratory products stabilising

  6. Slide 6: Vast opportunity targeting GPCRs, however many high-value targets remain untapped

    Business Partnered Proprietary Strategic GPCRs/StaR® Financials Model GPCR Pipeline GPCR Pipeline Investment Vast opportunity targeting GPCRs, however many high-value targets remain untapped GPCRs are the backbone of the pharma industry Neurological disorders c.400 non-olfactory GPCR targets in the

  7. Slide 7: StaR technology enables us to stabilize and unlock GPCRs

    Business Partnered Proprietary Strategic GPCRs/StaR® Financials Model GPCR Pipeline GPCR Pipeline Investment StaR® technology enables us to stabilize and “unlock” GPCRs Revolution for GPCR structure-based discovery Difficulty drugging native/”wild-type” GPCRs Our solution: proprietary StaR® technolo

  8. Slide 8: Risk-balanced strategy to leverage leadership and capitalize on GPCR opportunity

    Business Partnered Proprietary Strategic GPCRs/StaR® Financials Model GPCR Pipeline GPCR Pipeline Investment Risk-balanced strategy to leverage leadership and capitalize on GPCR opportunity Creates and captures value Partnered (Traditional out-licensing/ ➢ Leverage strategic capabilities of partners

  9. Slide 9: Advancing a Partnered GPCR pipeline in multiple therapeutic areas

    Business Partnered Proprietary Strategic GPCRs/StaR® Financials Model GPCR Pipeline GPCR Pipeline Investment : Current stage Advancing a Partnered GPCR pipeline in multiple therapeutic areas : Next 12–15 months progress Balanced and diversified Product/Program Modality Indication Partner Discovery P

  10. Slide 10: Up to $6bn in potential economics secured from lead Partnered compounds

    Business Partnered Proprietary Strategic GPCRs/StaR® Financials Model GPCR Pipeline GPCR Pipeline Investment Up to $6bn in potential economics secured from lead Partnered compounds Provides potential source of non-dilutive financing Upfront Total Total Sales Total UF + Milestones Program / received

  11. Slide 11: Muscarinic M1 receptor agonist program for AD

    Business Partnered Proprietary Strategic GPCRs/StaR® Financials Model GPCR Pipeline GPCR Pipeline Investment Partnered with: Muscarinic M1 receptor agonist program for AD M1 AD A novel approach for symptomatic treatment of AD Phase 1b ➢ Donepezil inhibits cholinesterase, preventing the breakdown of

  12. Slide 12: HTL0018318 is a potential first-in-class therapy for AD

    Business Partnered Proprietary Strategic GPCRs/StaR® Financials Model GPCR Pipeline GPCR Pipeline Investment Partnered with: HTL0018318 is a potential first-in-class therapy for AD M1 AD Highly selective M1 receptor agonist derived from StaR® and SBDD Phase 1b Overview of the HTL0018318 muscarinic M

  13. Slide 13: Adenosine A2A antagonist program for cancer treatment

    Business Partnered Proprietary Strategic GPCRs/StaR® Financials Model GPCR Pipeline GPCR Pipeline Investment Partnered with: Adenosine A2A antagonist program for cancer treatment A2A Exciting I/O treatment approach Phase 1b I/O drugs – forecast sales for marketed products ($bn)1 Potential role of Ad

  14. Slide 14: AZD4635 is a highly potent and selective A2A antagonist

    Business Partnered Proprietary Strategic GPCRs/StaR® Financials Model GPCR Pipeline GPCR Pipeline Investment Partnered with: AZD4635 is a highly potent and selective A2A antagonist A2A The first A2A antagonist structurally derived from StaR® and SBDD Phase 1b Preclinical summary of AZD4635 Phase 1b

  15. Slide 15: Proprietary pipeline now led by M1 DLB opportunity in Japan

    Business Partnered Proprietary Strategic GPCRs/StaR® Financials Model GPCR Pipeline GPCR Pipeline Investment : Current stage Proprietary pipeline now led by M1 DLB opportunity in Japan : Next 12–15 months progress Focus on selected rare/orphan and specialty indications or markets Product/Program Mod

  16. Slide 16: Sosei is advancing HTL0018318 for DLB in Japan

    Business Partnered Proprietary Strategic GPCRs/StaR® Financials Model GPCR Pipeline GPCR Pipeline Investment Sosei is advancing HTL0018318 for DLB in Japan M1 DLB Highly selective M1 receptor agonist designed by StaR® and SBDD Phase 2 ready Dementia with Lewy Bodies (DLB) Overview of our M1 program

  17. Slide 17: Strategic investment in saRNA technology

    Business Partnered Proprietary Strategic GPCRs/StaR® Financials Model GPCR Pipeline GPCR Pipeline Investment Strategic investment in saRNA technology CEBPA CEBPA1 is an attractive, previously ‘undruggable’ target in liver disease Phase 1/2a In May 2017, we acquired a strategic 25.6% stake in MiNA, w

  18. Slide 18: Continuing to invest and scale the business

    Business Partnered Proprietary Strategic GPCRs/StaR® Financials Model GPCR Pipeline GPCR Pipeline Investment Continuing to invest and scale the business Allergan upfront milestone in FY2016 drives P&L variance % change % change (JPY m)1 FY2015 FY2016 (FY15 vs FY16) H1 FY 2016 H1 FY 2017 (H116 vs H11

  19. Slide 19: Thank you!

    Listed 2004 in Tokyo (TSE Mothers: 4565) Global management team Thank you! Main scientific campus in the U.K. Market capitalization: c.$2.0bn ➢ World-leader in GPCR-focused drug design based on unique IP protected StaR®1 GPCR technology & enabled SBDD2 platform ➢ Partnered clinical-stage pipeline in

  20. Slide 20: Locations

    Locations SOSEI GROUP HEPTARES THERAPEUTICS PMO Hanzomon 11F BioPark, Broadwater Road 2-1 Kojimachi, Chiyoda-ku Welwyn Garden City Tokyo 102-0083 Japan Hertfordshire AL7 3AX United Kingdom 2nd Floor, London BioScience Innovation Centre Grabenstrasse 11a, 2 Royal College Street CH-8952 Schlieren Züri

Sosei Group — 36th Annual J.P. Morgan Healthcare Conference (January 2018) on 6ix